Knott David M Jr Grows Stock Position in Viridian Therapeutics, Inc. $VRDN

Knott David M Jr increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 27.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 116,574 shares of the company’s stock after acquiring an additional 25,091 shares during the period. Viridian Therapeutics comprises about 1.0% of Knott David M Jr’s holdings, making the stock its 18th largest holding. Knott David M Jr owned approximately 0.12% of Viridian Therapeutics worth $2,516,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd purchased a new position in Viridian Therapeutics in the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC lifted its position in Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after purchasing an additional 1,886 shares during the period. US Bancorp DE boosted its stake in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares during the period. Finally, Clearstead Advisors LLC grew its holdings in shares of Viridian Therapeutics by 3,868.3% in the third quarter. Clearstead Advisors LLC now owns 5,000 shares of the company’s stock worth $108,000 after purchasing an additional 4,874 shares during the last quarter.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. UBS Group assumed coverage on shares of Viridian Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. William Blair assumed coverage on shares of Viridian Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Royal Bank Of Canada lowered their price objective on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Finally, Wells Fargo & Company increased their target price on shares of Viridian Therapeutics from $26.00 to $29.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.43.

Insider Activity

In other news, insider Jennifer Tousignant sold 2,272 shares of the stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.58% of the company’s stock.

Viridian Therapeutics Trading Down 1.9%

NASDAQ:VRDN opened at $28.34 on Friday. The company has a 50-day moving average price of $30.73 and a 200-day moving average price of $26.79. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -8.61 and a beta of 1.00. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $15.75 million. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.